COMPANY

OncoTAb

HQ: Charlotte, NC source · oncotab.com ↗ · Southeast

Keywords: oncology cancer

Location: Charlotte, NC · source · Oct 14, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.13M (SBIR Phase II 1R44CA306447-01A1, new, notice Jul 17, 2026). NIH RePORTER 1R44CA306447-01A1 (Jul 17, 2026)
Evidence (1 event)
- Jul 17, 2026 · NIH RePORTER 1R44CA306447-01A1
  Organization: ONCOTAB, INC; City/State: CHARLOTTE, NC; Project number: 1R44CA306447-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1130587; Administering IC: National Cancer Institute; Project title: Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 17, 2026 Grant Government grant — SBIR: $1.13M (annual award, as published), announced Jul 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
May 22, 2025 Grant Government grant — STTR: $400,000 (annual award, as published), announced May 22, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Last 2 years.

Jul 17, 2026 Government grant — SBIR: $1.13M (annual award, as published), announced Jul 17, 2026. Agency: NIH/NCI. Source: government award database. source ↗
May 22, 2025 Government grant — STTR: $400,000 (annual award, as published), announced May 22, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Annual award amounts. Total $1.1M.

Sep 24, 2021 NIH award 1R41CA265619-01 FY2021: $260,588 awarded for that fiscal year; activity R41 (STTR); PI MUKHERJEE, PINKU; recipient as written: ONCOTAB, INC, CHARLOTTE, NC. The use of tMUC1/CD3 bispecific antibody to contro source ↗
Sep 21, 2021 NIH award 1R41CA265655-01 FY2021: $400,000 awarded for that fiscal year; activity R41 (STTR); PI MUKHERJEE, PINKU; recipient as written: ONCOTAB, INC, CHARLOTTE, NC. An integrated strategy using a serum and imaging b source ↗
May 26, 2016 NIH award 1R41CA195947-01A1 FY2016: $182,461 awarded for that fiscal year; activity R41 (STTR); PI MUKHERJEE, PINKU; recipient as written: ONCOTAB, INC, CHARLOTTE, NC. Novel immunotherapy strategy for treatment of pa source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 261201600013C-0-0-1 FY2016: $300,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI DAS ROY, LOPAMUDRA; recipient as written: ONCOTAB, INC, CHARLOTTE, NC. IGF::OT::IGF DEVE source ↗